Corona Remedies Ltd. IPO

We are an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. Our diversified product portfolio comprises 71 brands catering to a ... range of therapeutic areas such as women’s healthcare, cardio-diabeto, pain management and urology, among others, as of June 30, 2025. Of our targeted therapeutic areas, our women’s healthcare segment contributed to 28.56% (or ?4,080.26 million), cardiodiabeto (comprising cardio-vascular and anti-diabetic areas) contributed 23.38% (or ?3,339.96 million), pain management contributed 11.79% (or ?1,684.38 million) and urology contributed 4.53% (or ?646.65 million) to our domestic sales for MAT June 2025. Read more

Our Company was originally incorporated as ‘CORONA Remedies Private Limited’, a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. ... Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders on October 24, 2024, and consequently, the name of our Company was changed to ‘CORONA Remedies Limited’. A fresh certificate of incorporation, upon conversion of our Company to a public limited company was issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024.

As of Financial Year 2025, the Indian domestic formulation market, holding a market size of approximately ?2.3 trillion, accounted for approximately 2% of the overall global pharmaceutical market. India possesses an ecosystem to develop and manufacture pharmaceuticals, with companies having ... state-of-the-art facilities and skilled/ technical manpower. The domestic market (consumption) logged a healthy CAGR of 9% between Financial Years 2020 and 2025. It is expected to clock a CAGR of 8-9% to reach ?3.3-3.5 trillion by Financial Year 2030, aided by strong demand on account of rising incidences of chronic diseases, awareness and access to quality healthcare. Read more